Because routine vaccination against smallpox was discontinued in 1971 for civilians and in 1990 for military personnel, most young adults and children have not been exposed to the smallpox vaccine. Subsequently, healthcare providers have limited experience administering the smallpox vaccine and monitoring for potential adverse reactions, particularly in the adult population.

The vaccine is safe, and adverse reactions are mild and infrequent. The most commonly reported reactions by adolescents and adults in clinical studies were pain at the injection site, headache, and fatigue. These respond to simple measures (ibuprofen or acetaminophen) and resolve spontaneously within a few days. Meningococcal immunization should be deferred during any acute illness. The vaccine should not be administered to pregnant women or individuals sensitive to components of the vaccine.

Vaccination within 3 days of exposure will completely prevent or significantly modify smallpox in the vast majority of persons. Vaccination 4 to 7 days after exposure likely offers some protection from disease or may modify the severity of disease. (added Nov 13, 2002)

Past experience indicates that the first dose of the vaccine offers protection from smallpox for 3 to 5 years, with decreasing immunity thereafter. If a person is vaccinated again later, immunity lasts longer. (added Nov 13, 2002)

No. The smallpox vaccine does not contain smallpox virus and cannot spread or cause smallpox. However the vaccine does contain another virus called vaccinia, which is “live” in the vaccine. Because the virus is live, it can spread to other parts of the body or to other people from the vaccine site. This can be prevented through proper care of the vaccination site (e.g., hand washing and careful disposal of used bandages). (added Nov 13, 2002) Yes.

If the contraindication is eczema, the risk is that you develop disfiguring disseminated skin lesions, termed "eczema vaccinatum". If the contraindication is HIV/AIDS, there is too little data to be sure about the probability and type of risk, since routine smallpox vaccination stopped in 1972 in the USA and the HIV epidemic was not recognized until 1981.

Always a risk-benefit balance, but if you have a substantial exposure (e.g., face to face contact with known smallpox patient), then you probably should get the vaccine. Given face to-face exposure to smallpox, there is NO absolute contraindication to vaccination. VIG might be given along with the vaccine to lessen the risk of severe vaccine reactions, if VIG is available.

Tarceva has no known contraindications, and its safety profile has been established in more than 2,000 patients in completed clinical trials. In the single-agent NSCLC Phase III trial, the most common side effects-rash and diarrhea-were generally mild to moderate. Each resulted in treatment discontinuation in 1% of Tarceva-treated patients.

The side effects that most often cause problems are: Daytime hangover or sleepiness; dizziness; drowsiness; poor coordination; reduced mental alertness; impaired judgment; reduced physical alertness; trouble paying attention; problems with memory or learning; excitement; restlessness; reduced tolerance for alcohol, narcotics and other sedatives.

No. There are no reported cases of adverse side effects to date ever since Libidus was launched 1-1/2 years ago. However, a small percentage of users with pre-existing poor blood circulation did experience a slight headache after consuming Libidus. This is due to improved blood flow to the brain. However, regular consumption of Libidus will eliminate this problem.

The vaccine is safe, and adverse reactions are mild and infrequent. The most commonly reported reactions by adolescents and adults in clinical studies were pain at the injection site, headache, and fatigue. These respond to simple measures (ibuprofen or acetaminophen) and resolve spontaneously within a few days.

While temporary redness and swelling can occur at the injection sites, these effects usually fade in just a few days.

After treatment, there may be redness, swelling, bruising, bumps, or tenderness. This usually subsides within days.

with all endometrial ablation procedures, serious injury or death can occur. The following adverse effects could occur or have been reported in association with the use of NovaSure4: Complications with pregnancy (Note: Pregnancy following endometrial ablation is very dangerous for both the mother and the fetus)

In clinical studies, side effects with plant stanol esters were comparable to placebo. Plant stanol esters have an excellent safety profile. This safety record is further supported by ten years of experience with plant stanol esters consumed as BENECOL? Spread.

In general, most procedures have a low risk of adverse side effects. Some patients experience pigment changes in the skin color. If this occurs, the skin will typically return to normal pigmentation over time. All treatment results are individual.

Side effects are any undesired effects of the study medication. These effects may include headache, nausea, skin irritation, or other physical problems.

Nutritional yeasts are not live yeast cells. Saccharomyces cerevisiae, the type of nutritional yeast included in EpiCor has been dried at temperatures high enough to render it inactive, therefore it is not associated with systemic yeast infections, vaginal yeast infections, or thrush. FDA dietary supplement regulations prevent companies from making health claims on dietary products.